OBJECTIVE: To evaluate the in vivo therapeutic efficacy of chloroquine (CQ), sulfadoxine-pyrimethamine (SP) and mefloquine (MQ) in children presenting with uncomplicated malaria in Benin. METHODS:Drug efficacy was tested according to the WHO in vivo 28-day protocol. For failures that occurred after 7 days of follow-up, paired pre- and post-treatment blood samples were genotyped at msp1 and msp2 loci to distinguish new infections and recrudescent strains. Children enrolled were randomly assigned to a therapeutic group (CQ, n=14; SP, n=42; MQ, n=44). The number of CQ treatment was intentionally restricted after 1 month, as its use was considered to constitute a danger for children. RESULTS:Chloroquine and SP showed very high failure rates (85.7% and 50%, respectively), whereas MQ treatment was successful in 97.5%. The molecular tool allowed to re-evaluate two new infections previously considered as failures. CONCLUSIONS:Chloroquine should no longer be used to treat children presenting with Plasmodium falciparum malaria in Benin.
RCT Entities:
OBJECTIVE: To evaluate the in vivo therapeutic efficacy of chloroquine (CQ), sulfadoxine-pyrimethamine (SP) and mefloquine (MQ) in children presenting with uncomplicated malaria in Benin. METHODS: Drug efficacy was tested according to the WHO in vivo 28-day protocol. For failures that occurred after 7 days of follow-up, paired pre- and post-treatment blood samples were genotyped at msp1 and msp2 loci to distinguish new infections and recrudescent strains. Children enrolled were randomly assigned to a therapeutic group (CQ, n=14; SP, n=42; MQ, n=44). The number of CQ treatment was intentionally restricted after 1 month, as its use was considered to constitute a danger for children. RESULTS:Chloroquine and SP showed very high failure rates (85.7% and 50%, respectively), whereas MQ treatment was successful in 97.5%. The molecular tool allowed to re-evaluate two new infections previously considered as failures. CONCLUSIONS:Chloroquine should no longer be used to treat children presenting with Plasmodium falciparum malaria in Benin.
Authors: Alexander K Rowe; Faustin Onikpo; Marcel Lama; Dawn M Osterholt; Michael S Deming Journal: Am J Public Health Date: 2011-05-12 Impact factor: 9.308
Authors: Agnès Le Port; Gilles Cottrell; Célia Dechavanne; Valérie Briand; Aziz Bouraima; José Guerra; Isabelle Choudat; Achille Massougbodji; Benjamin Fayomi; Florence Migot-Nabias; André Garcia; Michel Cot Journal: Am J Trop Med Hyg Date: 2011-02 Impact factor: 2.345
Authors: Matthew Cairns; Roly Gosling; Ilona Carneiro; Samwel Gesase; Jacklin F Mosha; Ramadhan Hashim; Harparkash Kaur; Martha Lemnge; Frank W Mosha; Brian Greenwood; Daniel Chandramohan Journal: PLoS One Date: 2010-03-01 Impact factor: 3.240